









Markets
/
Stocks
/
nasdaq-adma
/

ADMA Biologics Inc

ADMA

14.710USD

+0.190+1.31%

Close 11/10, 16:00（ET）Quotes delayed by 15 min

3.51BMarket Cap

16.74P/E TTM



ADMA Biologics Inc

14.710

+0.190+1.31%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of ADMA Biologics Inc

Currency: USD Updated: 2025-11-10

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ADMA Biologics Inc's Score

Industry at a Glance

Industry Ranking

30 / 159

Overall Ranking

78 / 4611

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

27.250

Target Price

+87.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

ADMA Biologics Inc Highlights

StrengthsRisks

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 176.77% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is 16.58, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 215.13M shares, decreasing 10.61% quarter-over-quarter.

Held by John Hussman

Star Investor John Hussman holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-10

The company's current financial score is 8.83, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 134.22M, representing a year-over-year increase of 12.00%, while its net profit experienced a year-over-year increase of 1.45%.

Score

Industry at a Glance

Previous score

8.83

Change



Financials

8.54

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.82

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.81

Key Metrics

Free cash flow

No Data

ADMA Biologics Inc's Company Valuation

Currency: USD Updated: 2025-11-10

The company’s current valuation score is 7.29, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 16.58, which is 709.24% below the recent high of 134.13 and 3912.90% above the recent low of -632.00.

Score

Industry at a Glance

Previous score

7.29

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 30/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-10

The company’s current earnings forecast score is 8.50, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for ADMA Biologics Inc is 30.00, with a high of 32.00 and a low of 17.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

27.250

Target Price

+87.67%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

ADMA Biologics Inc

ADMA

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-10

The company’s current price momentum score is 7.37, which is higher than the Pharmaceuticals industry's average of 7.09. Sideways: Currently, the stock price is trading between the resistance level at 15.94 and the support level at 13.62, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.21

Change

0.16

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.081

Sell

RSI(14)

46.375

Neutral

STOCH(KDJ)(9,3,3)

40.047

Neutral

ATR(14)

0.751

High Vlolatility

CCI(14)

-111.158

Sell

Williams %R

59.052

Sell

TRIX(12,20)

-0.021

Sell

StochRSI(14)

57.602

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

14.652

Buy

MA10

15.048

Sell

MA20

15.002

Sell

MA50

15.321

Sell

MA100

16.537

Sell

MA200

17.857

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-10

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 90.39%, representing a quarter-over-quarter decrease of 4.22%. The largest institutional shareholder is The Vanguard, holding a total of 20.92M shares, representing 8.79% of shares outstanding, with 14.63% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

33.35M

-2.47%

The Vanguard Group, Inc.

Star Investors

21.31M

+26.94%

State Street Investment Management (US)

12.08M

+5.57%

Invesco Advisers, Inc.

10.20M

+5.24%

Geode Capital Management, L.L.C.

5.91M

+4.33%

Dimensional Fund Advisors, L.P.

4.76M

-2.00%

American Century Investment Management, Inc.

4.61M

+8.43%

Thrivent Asset Management, LLC

3.32M

+78.10%

Nuveen LLC

4.10M

+18.45%

Grossman (Adam S)

3.75M

-0.16%

Risk Assessment

Currency: USD Updated: 2025-11-10

The company’s current risk assessment score is 5.86, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.47. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.